Having shown that P. aeruginosa infection induces a specific antibody against PE, we next determined whether this prior infection altered the efficacy of IL13-PE therapy in a pulmonary fibrosis model induced by the intratracheal introduction of bleomycin sulfate. The gene discussed is IL13; the disease is infection.